SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors
DOI: https://doi.org/10.2147/ijn.s458323
IF: 7.033
2024-06-15
International Journal of Nanomedicine
Abstract:Sang-Soo Kim, 1, 2 Manish Moghe, 1 Antonina Rait, 1 Kathryn Donaldson, 1 Joe B Harford, 2 Esther H Chang 1 1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA; 2 SynerGene Therapeutics, Inc, Potomac, MD, USA Correspondence: Esther H Chang, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road N.W., Research Building E420, Washington, DC, 20057, USA, Email Purpose: Atypical teratoid rhabdoid tumor (ATRT) is a deadly, fast-growing form of pediatric brain cancer with poor prognosis. Most ATRTs are associated with inactivation of SMARCB1, a subunit of the chromatin remodeling complex, which is involved in developmental processes. The recent identification of SMARCB1 as a tumor suppressor gene suggests that restoration of SMARCB1 could be an effective therapeutic approach. Methods: We tested SMARCB1 gene therapy in SMARCB1-deficient rhabdoid tumor cells using a novel tumor-targeted nanomedicine (termed scL-SMARCB1) to deliver wild-type SMARCB1. Our nanomedicine is a systemically administered immuno-lipid nanoparticle that can actively cross the blood-brain barrier via transferrin receptor-mediated transcytosis and selectively target tumor cells via transferrin receptor-mediated endocytosis. We studied the antitumor activity of the scL-SMARCB1 nanocomplex either as a single agent or in combination with traditional treatment modalities in preclinical models of SMARCB1-deficient ATRT. Results: Restoration of SMARCB1 expression by the scL-SMARCB1 nanocomplex blocked proliferation, and induced senescence and apoptosis in ATRT cells. Systemic administration of the scL-SMARCB1 nanocomplex demonstrated antitumor efficacy as monotherapy in mice bearing ATRT xenografts, where the expression of exogenous SMARCB1 modulates MYC-target genes. scL-SMARCB1 demonstrated even greater antitumor efficacy when combined with either cisplatin-based chemotherapy or radiation therapy, resulting in significantly improved survival of ATRT-bearing mice. Conclusion: Collectively, our data suggest that restoring SMARCB1 function via the scL-SMARCB1 nanocomplex may lead to therapeutic benefits in ATRT patients when combined with traditional chemoradiation therapies. Keywords: lipid nanoparticle, nanodelivery, SMARCB1, gene therapy, atypical teratoid rhabdoid tumor Graphical Brain cancer is one of the leading causes of cancer-associated deaths among children. 1 Current treatment modalities (eg, surgical resection, intensive chemotherapy, and radiation therapy) have shown limited effectiveness. Moreover, current treatment options often cause nonspecific cytotoxic effects that negatively affect the development of the young patient's brain, resulting in long-term neurological deficits. In particular, atypical teratoid rhabdoid tumor (ATRT) is a rare but highly malignant form of brain cancer that predominantly affects children under three years. 2,3 The median age at diagnosis is approximately 17 months, and patients typically survive less than one year after diagnosis. 2,4 Currently, there is no definitive standard of care for ATRT, and traditional treatments are not effective enough to stop aggressive progression of the disease. Given the dismal prognosis associated with ATRT, better treatment approaches are urgently needed to improve the treatment outcomes in these very young patients. Although genomic instability is a common feature of most malignant cells, 5 ATRT genomes are highly stable. Most ATRTs contain less than ten coding mutations, and large chromosome gain or loss is uncommon. 6–8 The only recurring molecular abnormality that characterizes ATRT is the inactivation of the SMARCB1 gene, which is observed in nearly 98% of ATRT patients. 9 SMARCB1 encodes a core subunit of the SWI/SNF chromatin remodeling complex that contributes to developmental processes. Although up to 20% of human cancers contain a loss-of-function mutation in the SWI/SNF complex, its role in tumor suppression remains understudied. 10 It was only recent that several studies have revealed that SMARCB1 is a tumor suppressor with its loss required for rhabdoid tumorigenesis. 3,11 The precise mechanism through which SMARCB1 can act as a tumor suppressor remains to be fully understood. 7,11–15 In rhabdoid tumors, inactivation of SMARCB1 can drive proliferation by altering the expression of multiple pro-oncogenic pathways. 16–22 Importantly, loss of SMARCB1 also reduces the efficacy of conventional anti-cancer treatments, such as radiation and chemotherapy. 23,24 Thus, restora -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology